Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6382617 | 0.80 | TRPA1 (0.44) | TRPA1MAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6389633 | 0.80 | TRPA1 (0.62) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL31255993 | 0.80 | TRPA1 (0.44) | TRPA1MAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL118494 | 0.79 | ROCK1 (0.39) | TRPA1MAPTSMN1; SMN2PLAUKDM4E | |
| SCHEMBL18318359 | 0.79 | PLAU (0.47) | TRPA1MAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8934159 | 0.79 | TRPA1 (0.61) | TRPA1MAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL15195532 | 0.79 | TNF (0.46) | TRPA1MAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL24168856 | 0.78 | TSHR (0.44) | CYP1A2CYP2D6TDP1TSHRGRM4 | |
| SCHEMBL6380931 | 0.77 | TRPA1 (0.43) | TRPA1MAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9883177 | 0.76 | ROCK1 (0.42) | TRPA1MAPTCYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116348109-B | Piperazine derivative, and preparation method and application thereof | 浙江海正药业股份有限公司 | 2025-01-21 | — | — | CN | disclosed |
| US-20230373972-A1 | PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230373972-A1 | PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230373972-A1 | PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| EP-4215525-A1 | PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Hisun Pharmaceutical Co., Ltd. (CN) | 2023-07-26 | — | — | EP | disclosed |
| CN-116348109-A | Piperazine derivative, and preparation method and application thereof | 浙江海正药业股份有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-11618748-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-20210363141-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2021-11-25 | — | — | US | disclosed |
| US-11028081-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3828172-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | Aerie Pharmaceuticals, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| WO-2010126626-A2 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100280011-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2010-11-04 | — | — | US | disclosed |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | WAKABAYASHI TOSHIAKI | 2010-10-21 | — | — | US | disclosed |
| EP-1243583-B1 | HETEROCYCLIC COMPOUNDS HAVING SULFONAMIDE GROUPS | EISAI CO LTD (JP) | 2005-09-28 | — | — | EP | disclosed |
| US-20050176712-A1 | Integrin expression inhibitor | EISAI CO., LTD. | 2005-08-11 | — | — | US | disclosed |
| US-6787534-B2 | SUBSTITUTED QUINOLINE AND ISOQUINOLINE ANTIANGIOGENIC AGENTS; SULFONYLUREAS | EISAI CO., LTD. (JP) | 2004-09-07 | — | — | US | disclosed |
| US-20040018192-A1 | Integrin expression inhibitors | EISAI CO., LTD. (JP) | 2004-01-29 | — | — | US | disclosed |
| US-20030144507-A1 | Sulfonamide-containing heterocyclic compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-1258252-A1 | INTEGRIN EXPRESSION INHIBITORS | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| EP-1243583-A1 | HETEROCYCLIC COMPOUNDS HAVING SULFONAMIDE GROUPS | Eisai Co., Ltd. (JP) | 2002-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176712-A1 | Integrin expression inhibitor | ITGB5, ITGB1, ITGB2 | TRPA1 304/4885MAPT 3398/4885CYP1A2 3959/4885 |
| US-11618748-B2 | Dual mechanism inhibitors for the treatment of disease | RHOA, SLC6A2, ROCK2 | TRPA1 3206/4885MAPT 66/4885CYP1A2 1339/4885 |
| US-11028081-B2 | Dual mechanism inhibitors for the treatment of disease | RHOA, SLC6A2, ROCK2 | TRPA1 3206/4885MAPT 66/4885CYP1A2 1339/4885 |
| US-20210363141-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | TRPA1 3206/4885MAPT 66/4885CYP1A2 1339/4885 |
| US-20230373972-A1 | PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | F7, F11, HABP2 | TRPA1 3922/4885MAPT 4565/4885CYP1A2 480/4885 |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | ITGB5, ITGB1, ITGB2 | TRPA1 304/4885MAPT 3398/4885CYP1A2 3959/4885 |
| US-20100280011-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | TRPA1 3206/4885MAPT 66/4885CYP1A2 1339/4885 |
| US-20040018192-A1 | Integrin expression inhibitors | ITGB1, ITGB4, ITGB5 | TRPA1 427/4885MAPT 3572/4885CYP1A2 4021/4885 |
| US-20030144507-A1 | Sulfonamide-containing heterocyclic compounds | SLC5A2, SLC5A1, CBR3 | TRPA1 1210/4885MAPT 4324/4885CYP1A2 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.